EP 0463157 A4 19920603 - LFA-3 AS A VACCINE ADJUVANT
Title (en)
LFA-3 AS A VACCINE ADJUVANT
Publication
Application
Priority
US 46914090 A 19900124
Abstract (en)
[origin: WO9111194A1] Vaccines comprising an immunogen and, as an adjuvant, LFA-3 or a fragment of LFA-3 capable of binding to CD2, a surface receptor on T-lymphocytes, are disclosed. LFA-3 has been found to markedly enhance the proliferation of activated T-cells and thus is capable of augmenting the immune response. Methods of vaccination in which LFA-3 is employed in conjunction with an immunogenic inoculum are also disclosed.
IPC 1-7
IPC 8 full level
A61K 39/29 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); C07K 14/705 (2006.01)
CPC (source: EP)
A61K 39/12 (2013.01); A61K 39/292 (2013.01); A61K 39/39 (2013.01); A61K 39/395 (2013.01); C07K 14/70528 (2013.01); A61K 2039/55516 (2013.01); C12N 2730/10134 (2013.01); Y02A 50/30 (2017.12)
Citation (search report)
- [X] WO 8912458 A1 19891228 - CELL MED INC [US]
- [X] WO 8910938 A1 19891116 - DANA FARBER CANCER INST INC [US]
- [X] CHEMICAL ABSTRACTS, vol. 108, no. 11, 14th March 1988, page 502, abstract no. 92752w, Columbus, Ohio, US; G. TIEFENTHALER et al.: "Purified lymphocyte function-associated antigen-3 and T11 target structure are active in CD2-mediated T cell stimulation" & EUR. J. IMMUNOl. 1987, 17(12), 1847-50
- See references of WO 9111194A1
Designated contracting state (EPC)
AT BE CH DE DK ES FR GB IT LI LU NL SE
DOCDB simple family (publication)
WO 9111194 A1 19910808; AU 7300091 A 19910821; CA 2049931 A1 19910725; EP 0463157 A1 19920102; EP 0463157 A4 19920603; JP H04506666 A 19921119
DOCDB simple family (application)
US 9100508 W 19910124; AU 7300091 A 19910124; CA 2049931 A 19910124; EP 91904441 A 19910124; JP 50484891 A 19910124